{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:57:16Z","timestamp":1781636236042,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>EZH2 is a histone methyltransferase and a key component of polycomb repressive complex 2 (PRC2). It plays a critical role in genome remodeling, gene regulation and acts through PRC2-dependent and independent mechanisms, which comprise methylation of histone and non-histone substrates, and transcriptional activation through different transcriptional complexes. EZH2 is involved in many cancers, but its role in hepatoblastoma is poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Potential correlation between\n                      <jats:italic>EZH2<\/jats:italic>\n                      mRNA expression and clinical parameters was analyzed by computational and histological approaches using seven published transcriptomic datasets and tissue samples from patients with hepatoblastoma. EZH2 molecular function was deciphered using molecular approaches, gain- and loss-of-function genetic tools, proteomics, immunohistochemistry, pharmacological drugs, 2D cell- and spheroid-based assays, and four different animal models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our data show that\n                      <jats:italic>EZH2<\/jats:italic>\n                      mRNA expression correlated with poor prognostic markers such as tumor proliferation, and patients\u2019 death and shorter survival. EZH2 protein potentiated hepatoblastoma cell proliferation, migration, survival and cisplatin resistance through its histone methyltransferase activity by repressing\n                      <jats:italic>DUSP5<\/jats:italic>\n                      , and transcriptionally inducing\n                      <jats:italic>DUSP9<\/jats:italic>\n                      and\n                      <jats:italic>HMGCR<\/jats:italic>\n                      . In vivo EZH2 sustained tumor cell proliferation, and tumor development and angiogenesis. The EZH2 inhibitor GSK126 synergized with HMG-CoA reductase inhibitor statins to eradicate hepatoblastoma cells in vitro and block tumor development in mice. This combination was also very effective on various hepatoblastoma and non-hepatoblastoma tumor cell lines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Collectively, our data showed that the protein EZH2 promotes hepatoblastoma development, partly through its histone methyltransferase activity, by differentially modulating the expression of\n                      <jats:italic>DUSP5<\/jats:italic>\n                      ,\n                      <jats:italic>DUSP9<\/jats:italic>\n                      and\n                      <jats:italic>HMGCR<\/jats:italic>\n                      genes and by supporting the MAPK\/ERK pathway in hepatoblastoma cells already displaying high Wnt signal activity. EZH2 inhibitors triggered lipid synthesis in hepatoblastoma cells and synergized with cholesterol-lowering statins to block hepatoblastoma development in vitro and in vivo. Therefore, we demonstrate the key role of EZH2 in proliferative hepatoblastoma and the therapeutic benefit of combining EZH2 inhibitor and statin to treat patients with cancer.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-025-02474-9","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:34:42Z","timestamp":1771846482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-2856","authenticated-orcid":false,"given":"Fatma Zohra","family":"Khoubai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Calovoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Guillorit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Carrillo-Reixach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"del Rio-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Simon","family":"Coma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Avignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Mora Charrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Fedou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-4797","authenticated-orcid":false,"given":"Jean-William","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Royo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-3259","authenticated-orcid":false,"given":"Montse","family":"Domingo-S\u00e0bat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Th\u00e9z\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-Majid","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8974-6551","authenticated-orcid":false,"given":"Emilie","family":"Indersie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buddhi Prakash","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Tr\u00e9z\u00e9guet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Gontier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2738-0758","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lamoureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Guettier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0960-5116","authenticated-orcid":false,"given":"Martin","family":"Hagedorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4690-4027","authenticated-orcid":false,"given":"Carolina","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0479-6291","authenticated-orcid":false,"given":"Christophe F.","family":"Grosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2474_CR1","volume-title":"Hepatoblastoma. Sergi CM, editor Liver Cancer Brisbane (AU)","author":"J Hager","year":"2021","unstructured":"Hager J, Sergi CM. Hepatoblastoma. Sergi CM, editor Liver Cancer Brisbane (AU). Exon; 2021."},{"key":"2474_CR2","doi-asserted-by":"crossref","unstructured":"Meyers RL, Maibach R, Hiyama E, Haberle B, Krailo M, Rangaswami A et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children\u2019s Hepatic tumors International Collaboration. The lancet oncology 2016.","DOI":"10.1016\/S1470-2045(16)30598-8"},{"key":"2474_CR3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","volume":"14","author":"J Zsiros","year":"2013","unstructured":"Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013;14:834\u201342.","journal-title":"Lancet Oncol"},{"key":"2474_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MOP.0000000000000046","volume":"26","author":"P Czauderna","year":"2014","unstructured":"Czauderna P, Lopez-Terrada D, Hiyama E, Haberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014;26:19\u201328.","journal-title":"Curr Opin Pediatr"},{"key":"2474_CR5","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.jhep.2014.09.016","volume":"61","author":"MA Buendia","year":"2014","unstructured":"Buendia MA. Unravelling the genetics of hepatoblastoma: few mutations, what else? J Hepatol. 2014;61:1202\u20134.","journal-title":"J Hepatol"},{"key":"2474_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccr.2008.11.002","volume":"14","author":"S Cairo","year":"2008","unstructured":"Cairo S, Armengol C, De Reynies A, Wei Y, Thomas E, Renard CA, et al. Hepatic stem-like phenotype and interplay of Wnt\/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 2008;14:471\u201384.","journal-title":"Cancer Cell"},{"key":"2474_CR7","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1002\/hep.27243","volume":"60","author":"D Jia","year":"2014","unstructured":"Jia D, Dong R, Jing Y, Xu D, Wang Q, Chen L, et al. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology. 2014;60:1686\u201396.","journal-title":"Hepatology"},{"key":"2474_CR8","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jhep.2014.08.009","volume":"61","author":"M Eichenmuller","year":"2014","unstructured":"Eichenmuller M, Trippel F, Kreuder M, Beck A, Schwarzmayr T, Haberle B, et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol. 2014;61:1312\u201320.","journal-title":"J Hepatol"},{"key":"2474_CR9","unstructured":"Sumazin P, Chen Y, Trevino LR, Sarabia SF, Hampton OA, Patel K et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology 2016."},{"key":"2474_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/hep.29672","volume":"68","author":"KB Hooks","year":"2018","unstructured":"Hooks KB, Audoux J, Fazli H, Lesjean S, Ernault T, Dugot-Senant N, et al. New insights into diagnosis and therapeutic options for proliferative hepatoblastoma. Hepatology. 2018;68:89\u2013102.","journal-title":"Hepatology"},{"issue":"2","key":"2474_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jhep.2020.03.025","volume":"73","author":"J Carrillo-Reixach","year":"2020","unstructured":"Carrillo-Reixach J, Torrens L, Simon-Coma M, Royo L, Domingo-Sabat M, Abril-Fornaguera J, et al. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. J Hepatol. 2020;73(2):328\u201341.","journal-title":"J Hepatol"},{"key":"2474_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/hep.28888","volume":"65","author":"P Sumazin","year":"2017","unstructured":"Sumazin P, Chen Y, Trevino LR, Sarabia SF, Hampton OA, Patel K, et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology. 2017;65:104\u201321.","journal-title":"Hepatology"},{"key":"2474_CR13","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1158\/2159-8290.CD-20-1809","volume":"11","author":"TZ Hirsch","year":"2021","unstructured":"Hirsch TZ, Pilet J, Morcrette G, Roehrig A, Monteiro BJE, Molina L, et al. Integrated genomic analysis identifies driver genes and Cisplatin-resistant progenitor phenotype in pediatric liver cancer. Cancer Discov. 2021;11:2524\u201343.","journal-title":"Cancer Discov"},{"key":"2474_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000521595","volume":"11","author":"N Mosca","year":"2022","unstructured":"Mosca N, Khoubai FZ, Fedou S, Carrillo-Reixach J, Caruso S, Del Rio-Alvarez A, et al. LIM homeobox-2 suppresses hallmarks of adult and pediatric liver cancers by inactivating MAPK\/ERK and Wnt\/Beta-Catenin pathways. Liver Cancer. 2022;11:126\u201340.","journal-title":"Liver Cancer"},{"key":"2474_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/liv.14276","volume":"40","author":"A Ghousein","year":"2020","unstructured":"Ghousein A, Mosca N, Cartier F, Charpentier J, Dupuy JW, Raymond AA, et al. MiR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS\/RAF\/MEK\/ERK signalling inactivation. Liver Int. 2020;40:240\u201351.","journal-title":"Liver Int"},{"key":"2474_CR16","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/hep.27347","volume":"60","author":"ZG Han","year":"2014","unstructured":"Han ZG. Mutational landscape of hepatoblastoma goes beyond the Wnt-beta-catenin pathway. Hepatology. 2014;60:1476\u20138.","journal-title":"Hepatology"},{"key":"2474_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jhep.2023.05.031","volume":"79","author":"A Claveria-Cabello","year":"2023","unstructured":"Claveria-Cabello A, Herranz JM, Latasa MU, Arechederra M, Uriarte I, Pineda-Lucena A, et al. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma. J Hepatol. 2023;79:989\u20131005.","journal-title":"J Hepatol"},{"key":"2474_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/CCO.0000000000000390","volume":"29","author":"M Yamagishi","year":"2017","unstructured":"Yamagishi M, Uchimaru K. Targeting EZH2 in cancer therapy. Curr Opin Oncol. 2017;29:375\u201381.","journal-title":"Curr Opin Oncol"},{"key":"2474_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10.","journal-title":"Biomark Res"},{"key":"2474_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","volume":"40","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang Q. The roles of EZH2 in cancer and its inhibitors. Med Oncol. 2023;40:167.","journal-title":"Med Oncol"},{"key":"2474_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/his.12436","volume":"65","author":"K Schlachter","year":"2014","unstructured":"Schlachter K, Gyugos M, Halasz J, Lendvai G, Baghy K, Garami M, et al. High tricellulin expression is associated with better survival in human hepatoblastoma. Histopathology. 2014;65:631\u201341.","journal-title":"Histopathology"},{"key":"2474_CR22","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.3892\/mmr.2016.4864","volume":"13","author":"Y Wang","year":"2016","unstructured":"Wang Y, Xiao Y, Chen K, Chen S, Zhang M, Wu Z, et al. Enhancer of Zeste homolog 2 depletion arrests the proliferation of hepatoblastoma cells. Mol Med Rep. 2016;13:2724\u20138.","journal-title":"Mol Med Rep"},{"key":"2474_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1055\/s-0040-1722645","volume":"41","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Solinas A, Cairo S, Evert M, Chen X, Calvisi DF. Molecular mechanisms of hepatoblastoma. Semin Liver Dis. 2021;41:28\u201341.","journal-title":"Semin Liver Dis"},{"key":"2474_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30774","author":"K Glaser","year":"2023","unstructured":"Glaser K, Schepers EJ, Zwolshen HM, Lake CM, Timchenko NA, Karns RA, et al. EZH2 is a key component of hepatoblastoma tumor cell growth. Pediatr Blood Cancer. 2023. https:\/\/doi.org\/10.1002\/pbc.30774.","journal-title":"Pediatr Blood Cancer"},{"key":"2474_CR25","doi-asserted-by":"publisher","DOI":"10.31487\/j.EJMC.2018.01.003","volume-title":"Gene expression profiling in hepatoblastoma cases of the Japanese Study Group for Pediatric Liver Tumors-2 (JPLT-2) trial","author":"E Hiyama","year":"2019","unstructured":"Hiyama E. Gene expression profiling in hepatoblastoma cases of the Japanese Study Group for Pediatric Liver Tumors-2 (JPLT-2) trial. Science Repository OU; 2019. 2019-02-12."},{"key":"2474_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s42003-018-0077-8","volume":"1","author":"L Valanejad","year":"2018","unstructured":"Valanejad L, Cast A, Wright M, Bissig KD, Karns R, Weirauch MT, et al. PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma. Commun Biol. 2018;1:67.","journal-title":"Commun Biol"},{"key":"2474_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207\u201310.","journal-title":"Nucleic Acids Res"},{"key":"2474_CR28","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2474_CR29","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","volume":"25","author":"J Kim","year":"2018","unstructured":"Kim J, Lee Y, Lu X, Song B, Fong KW, Cao Q, et al. Polycomb- and Methylation-Independent roles of EZH2 as a transcription activator. Cell Rep. 2018;25:2808\u201320. e2804.","journal-title":"Cell Rep"},{"key":"2474_CR30","doi-asserted-by":"publisher","first-page":"16149","DOI":"10.18632\/oncotarget.24598","volume":"9","author":"E Indersie","year":"2018","unstructured":"Indersie E, Hooks KB, Capdevielle C, Fabre M, Dugot-Senant N, Desplat A, et al. Tracking cellular and molecular changes in a species-specific manner during experimental tumor progression in vivo. Oncotarget. 2018;9:16149\u201362.","journal-title":"Oncotarget"},{"key":"2474_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/hep4.1029","volume":"1","author":"E Indersie","year":"2017","unstructured":"Indersie E, Lesjean S, Hooks KB, Sagliocco F, Ernault T, Cairo S, et al. MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta-catenin and Wnt signaling. Hepatol Commun. 2017;1:168\u201383.","journal-title":"Hepatol Commun"},{"key":"2474_CR32","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1158\/1078-0432.CCR-18-4024","volume":"25","author":"J Puppe","year":"2019","unstructured":"Puppe J, Opdam M, Schouten PC, Jozwiak K, Lips E, Severson T, et al. EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to High-Dose Platinum-Based chemotherapy. Clin Cancer Res. 2019;25:4351\u201362.","journal-title":"Clin Cancer Res"},{"key":"2474_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms222111538","volume":"22","author":"FZ Khoubai","year":"2021","unstructured":"Khoubai FZ, Grosset CF. DUSP9, a dual-specificity phosphatase with a key role in cell biology and human diseases. Int J Mol Sci. 2021;22:1\u201321.","journal-title":"Int J Mol Sci"},{"key":"2474_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.bbamcr.2018.09.002","volume":"1866","author":"OM Seternes","year":"2019","unstructured":"Seternes OM, Kidger AM, Keyse SM. Dual-specificity MAP kinase phosphatases in health and disease. Biochimica et Biophysica Acta (BBA). 2019;1866:124\u201343.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"2474_CR35","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jhep.2014.05.015","volume":"61","author":"SB Gao","year":"2014","unstructured":"Gao SB, Xu B, Ding LH, Zheng QL, Zhang L, Zheng QF, et al. The functional and mechanistic relatedness of EZH2 and Menin in hepatocellular carcinoma. J Hepatol. 2014;61:832\u20139.","journal-title":"J Hepatol"},{"key":"2474_CR36","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1038\/s41467-018-07270-2","volume":"9","author":"S Stelloo","year":"2018","unstructured":"Stelloo S, Nevedomskaya E, Kim Y, Schuurman K, Valle-Encinas E, Lobo J, et al. Integrative epigenetic taxonomy of primary prostate cancer. Nat Commun. 2018;9:4900.","journal-title":"Nat Commun"},{"issue":"12","key":"2474_CR37","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/tcr.201800091","volume":"18","author":"R Fioravanti","year":"2018","unstructured":"Fioravanti R, Stazi G, Zwergel C, Valente S, Mai A. Six Years (2012\u20132018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2\u2010Pyridone Compounds. Chem Rec. 2018;18(12):1818\u201332.","journal-title":"Chem Rec"},{"key":"2474_CR38","first-page":"2120","volume":"9","author":"PM Yang","year":"2019","unstructured":"Yang PM, Hong YH, Hsu KC, Liu TP. P38alpha\/S1P\/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma. Am J Cancer Res. 2019;9:2120\u201339.","journal-title":"Am J Cancer Res"},{"key":"2474_CR39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41419-021-03760-2","volume":"12","author":"X Xu","year":"2021","unstructured":"Xu X, Chen J, Li Y, Yang X, Wang Q, Wen Y, et al. Targeting epigenetic modulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell carcinoma. Cell Death Dis. 2021;12:482.","journal-title":"Cell Death Dis"},{"key":"2474_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac018","volume":"4","author":"F Rahal","year":"2022","unstructured":"Rahal F, Capdevielle C, Rousseau B, Izotte J, Dupuy JW, Cappellen D, et al. An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect. Neuro-Oncol Adv. 2022;4:vdac018.","journal-title":"Neuro-Oncol Adv"},{"key":"2474_CR41","first-page":"3393","volume":"59","author":"G Alipour Talesh","year":"2020","unstructured":"Alipour Talesh G, Trezeguet V, Merched A. Hepatocellular Carcinoma Statins Biochem. 2020;59:3393\u2013400.","journal-title":"Hepatocellular Carcinoma Statins Biochem"},{"key":"2474_CR42","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1021\/acs.biochem.0c00477","volume":"59","author":"M Alannan","year":"2020","unstructured":"Alannan M, Fayyad-Kazan H, Trezeguet V, Merched A. Targeting lipid metabolism in liver cancer. Biochemistry. 2020;59:3951\u201364.","journal-title":"Biochemistry"},{"key":"2474_CR43","doi-asserted-by":"publisher","unstructured":"Han M, Bushong EA, Segawa M, Tiard A, Wong A, Brady MR et al. Spatial mapping of mitochondrial networks and bioenergetics in lung cancer. Nature 2023: 615, 712-719. https:\/\/doi.org\/10.1038\/s41586-023-05793-3","DOI":"10.1038\/s41586-023-05793-3"},{"key":"2474_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1746-1596-7-86","volume":"7","author":"S Hajosi-Kalcakosz","year":"2012","unstructured":"Hajosi-Kalcakosz S, Dezso K, Bugyik E, Bodor C, Paku S, Pavai Z, et al. Enhancer of Zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors. Diagn Pathol. 2012;7:86.","journal-title":"Diagn Pathol"},{"key":"2474_CR45","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/hep.21668","volume":"46","author":"Y Chen","year":"2007","unstructured":"Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, et al. Lentivirus-mediated RNA interference targeting enhancer of Zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology. 2007;46:200\u20138.","journal-title":"Hepatology"},{"key":"2474_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13:104.","journal-title":"J Hematol Oncol"},{"key":"2474_CR47","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1478-3231.2011.02729.x","volume":"32","author":"C Eicher","year":"2012","unstructured":"Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S. Treatment effects of the multikinase inhibitor Sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 Nu mice. Liver Int. 2012;32:574\u201381.","journal-title":"Liver Int"},{"key":"2474_CR48","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/bjc.2012.539","volume":"108","author":"C Eicher","year":"2013","unstructured":"Eicher C, Dewerth A, Thomale J, Ellerkamp V, Hildenbrand S, Warmann SW, et al. Effect of Sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts. Br J Cancer. 2013;108:334\u201341.","journal-title":"Br J Cancer"},{"key":"2474_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12922","volume":"54","author":"Z Ma","year":"2021","unstructured":"Ma Z, Gao X, Shuai Y, Wu X, Yan Y, Xing X, et al. EGR1-mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer. Cell Prolif. 2021;54:e12922.","journal-title":"Cell Prolif"},{"key":"2474_CR50","doi-asserted-by":"publisher","first-page":"109509","DOI":"10.18632\/oncotarget.22723","volume":"8","author":"B Liu","year":"2017","unstructured":"Liu B, Li J, Liu X, Zheng M, Yang Y, Lyu Q, et al. Long non-coding RNA HOXA11-AS promotes the proliferation HCC cells by epigenetically silencing DUSP5. Oncotarget. 2017;8:109509\u201321.","journal-title":"Oncotarget"},{"key":"2474_CR51","doi-asserted-by":"publisher","first-page":"e2997","DOI":"10.1038\/cddis.2017.328","volume":"8","author":"J Ding","year":"2017","unstructured":"Ding J, Li J, Wang H, Tian Y, Xie M, He X, et al. Long noncoding RNA CRNDE promotes colorectal cancer cell proliferation via epigenetically silencing DUSP5\/CDKN1A expression. Cell Death Dis. 2017;8:e2997.","journal-title":"Cell Death Dis"},{"key":"2474_CR52","first-page":"1116","volume":"24","author":"XY Wang","year":"2020","unstructured":"Wang XY, Jian X, Sun BQ, Ge XS, Huang FJ, Chen YQ. LncRNA ROR1-AS1 promotes colon cancer cell proliferation by suppressing the expression of DUSP5\/CDKN1A. Eur Rev Med Pharmacol Sci. 2020;24:1116\u201325.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2474_CR53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22:128\u201334.","journal-title":"Nat Med"},{"key":"2474_CR54","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/1535370218760283","volume":"243","author":"L Zheng","year":"2018","unstructured":"Zheng L, Li L, Lu Y, Jiang F, Yang XA. SREBP2 contributes to cisplatin resistance in ovarian cancer cells. Exp Biol Med (Maywood). 2018;243:655\u201362.","journal-title":"Exp Biol Med (Maywood)"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02474-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02474-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02474-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:41:58Z","timestamp":1781635318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-025-02474-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2474"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02474-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"3 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol using patients\u2019 samples was approved by the ethic committees of the French Government (BCT-Centre de Ressources biologiques, H\u00f4pital Le Kremlin-Bic\u00eatre, 94275 Le Kremlin-Bic\u00eatre, France; reference number: B-CRB-DE-PSAD13-004-01; cession number: 2018-ACP-BCT-01R; BRIF number: BB-0033-00089; N\u00b0ID-RCB-A00180-49; CPP N\u00b0CO-15-003; CNIL N\u00b0915640; CCTIRS N\u00b015.700; MESR N\u00b0 DC2009-939. Each patient provided informed consent before participation in the study. The study protocol using mice was approved by the ethical Committee of the French Government (APAFIS #32917-2021121316283534 v2, n\u00b0A-32917).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Drs C.F. Grosset, M Hagedorn and F.Z. Khoubai are co-inventors of a pending patent deposited by Aquitaine Science Transfer. Dr C.F. Grosset received a 2-year research grant from Aquitaine Science Transfer and is part of the scientific board of Paediatis. The other authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}